Extended Half-Life (EHL) Recombinant Factor VIII

Treatment for Hemophilia

Typical Dosage: Prophylaxis: 25-65 IU/kg 2 times per week or every 3-5 days; On-demand: 10-50 IU/kg

Effectiveness
90%
Safety Score
65%
Clinical Trials
2
Participants
8K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Prophylaxis: 25-65 IU/kg 2 times per week or every 3-5 days; On-demand: 10-50 IU/kg
Time to Effect
immediate
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$400,000
Monitoring:$5,000
Side Effect Mgmt:$8,000
Total Annual:$413,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
ICER
$110,000/QALY
QALYs Gained
0.35
Outcome-Based Costs
Cost per Responder
$434,736.84
Comparison vs Standard Half-Life Recombinant Factor VIII
Cost Difference
+$50,000/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Extended Half-Life (EHL) Recombinant Factor VIII Outcomes

for Hemophilia

Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+95%
Common Side Effects
Inhibitor development
+10%
Allergic reactions
+0.5%
Injection site reactions
+3%

Sources:

nih.gov
nih.gov
htct.com.br

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
1 active trial recruiting for Extended Half-Life (EHL) Recombinant Factor VIII in Hemophilia

Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A

NCT07439055ACTIVE NOT RECRUITINGPHASE2, PHASE3
View Study
18 participants
INTERVENTIONAL
Bangkok, Thailand
Started: Jun 1, 2025
Completed Clinical Trials
2 completed trials for Extended Half-Life (EHL) Recombinant Factor VIII in Hemophilia

A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate

NCT04876365COMPLETED
View Study
153 participants
OBSERVATIONAL
Hamilton, Canada
Started: Nov 30, 2021

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

NCT05042440COMPLETEDPHASE1
View Study
13 participants
INTERVENTIONAL
Sofia, Bulgaria
Started: Aug 11, 2021